Haleon’s EMEA Head Filippo Lanzi: There’s More To Innovation Than Rx-To-OTC Switch
Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment.
You may also be interested in...
A better than expected first-half performance has put Haleon on a sure footing for the rest of the year following its recent demerger from GSK.
As GSK prepares to launch its standalone consumer health business, Haleon, Tess Player, global head of expert and influencer marketing, talks to HBW Insight about the new company's plans to improve health inclusivity globally and empower 50 million consumers per year to self-care by 2025.
GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.